

Jelena Belic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2776298/publications.pdf>

Version: 2024-02-01

12
papers

713
citations

1040056

9
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

1525
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. <i>Genome Medicine</i> , 2013, 5, 30.	8.2	306
2	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	12.8	146
3	Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. <i>Nature Communications</i> , 2016, 7, 12008.	12.8	134
4	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. <i>International Journal of Cancer</i> , 2018, 143, 1236-1248.	5.1	37
5	mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 147-155.	1.6	23
6	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	3.7	23
7	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. <i>Npj Precision Oncology</i> , 2020, 4, 30.	5.4	13
8	Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. <i>Cancers</i> , 2020, 12, 1481.	3.7	13
9	A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. <i>International Journal of Cancer</i> , 2021, 148, 1452-1461.	5.1	10
10	Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models. <i>EMBO Molecular Medicine</i> , 2022, 14, .	6.9	6
11	Potentials, challenges and limitations of a molecular characterization of circulating tumor DNA for the management of cancer patients. <i>Laboratoriums Medizin</i> , 2016, 40, 323-334.	0.6	1
12	Characterisation and treatment of patients with castration-resistant metastatic prostate cancer (mCRPC) developing neuroendocrine clonal divergence (NCD): A case series. <i>Journal of Clinical Oncology</i> , 2017, 35, e16520-e16520.	1.6	0